C

Cara Therapeutics

CARA

0.35480
USD
0.0038
(1.08%)
Market Closed
Volume
612
EPS
0
Div Yield
0
P/E
-0
Market Cap
14,814,077
Related Instruments
A
ACB
-0.08000
(-1.30%)
6.06000 USD
C
CGC
-0.82500
(-10.86%)
6.77500 USD
C
CRON
-0.11000
(-4.49%)
2.34000 USD
H
HEXO
-0.03000
(-2.36%)
1.23000 USD
T
TLRY
-0.03500
(-1.73%)
1.98500 USD
Z
ZYNE
0
(0%)
0.000000 USD
News

Title: Cara Therapeutics

Sector: Healthcare
Industry: Biotechnology
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.